| 0.008 -0.009 (-52.38%) | 09-29 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0 | 1-year : | 0.01 |
| Resists | First : | 0 | Second : | 0.01 |
| Pivot price | 0 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0.06 |
MA(250) : | 0.23 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.1 |
D(3) : | 15.7 |
| RSI | RSI(14): 30.3 |
|||
| 52-week | High : | 0.76 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INFI ] has closed above bottom band by 12.8%. Bollinger Bands are 98.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Thu, 14 Sep 2023
Director Adelene Perkins Sells 410196 Shares of Infinity ... - GuruFocus.com
Tue, 05 Sep 2023
Three execs leave Infinity Pharmaceuticals after failed merger ... - The Business Journals
Thu, 24 Aug 2023
Calling all Infinity Pharmaceuticals, Inc. (INFI) Investors: Contact ... - PR Newswire
Tue, 08 Aug 2023
Why Is Infinity Pharmaceuticals (INFI) Stock Up 84% Today? - InvestorPlace
Tue, 25 Jul 2023
Infinity Pharmaceuticals Announces Value Preservation and ... - Yahoo Finance
Tue, 11 Jul 2023
Infinity Pharma (INFI) Stock Up on Advancing Cancer Study - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 8.191e+007 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 919 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.992e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 570.4 % |
| Return on Equity (ttm) | -60.8 % |
| Qtrly Rev. Growth | 2.57e+006 % |
| Gross Profit (p.s.) | -10.87 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.27391e+007 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.02 |
| Dividend | 0 |
| Forward Dividend | 2.21e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|